Tumor heterogeneity is one of the hallmarks of cancer and a challenge in the field of
oncology. Tumor heterogeneity is the main cause of drug resistance, leading to therapeutic …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

Background Detecting cancer at an early stage before clinical manifestation could be an
effective strategy to decrease cancer mortality. Thus, identifying liquid biopsy biomarkers …

Cancer remains a leading cause of death worldwide, partly owing to late detection which
entails limited and often ineffective therapeutic options. Most cancers lack validated …

The minimally—or non-invasive detection of circulating tumor-derived components in
biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential …

The biopsy is a gold standard method for tumor grading. However, due to its invasive nature,
it has sometimes proved fatal for brain tumor patients. As a result, a non-invasive computer …

The primary reason for high mortality rates among cancer patients is metastasis, where
tumor cells migrate through the bloodstream from the original site to other parts of the body …

Lung, breast, colorectal, and prostate cancers are the most incident worldwide. Optimal
population-based cancer screening methods remain an unmet need, since cancer detection …

Background Cancer is caused by a combination of genetic and epigenetic abnormalities.
Current cancer therapies are limited due to the complexity of their mechanism, underlining …